Cleveland Clinic's 20th Annual ASH Review
Playback speed
10 seconds
2019 ASH Review on R/R DLBCL: For Frail Unfit Patients, Addition of Polatuzumab Vedotin to BR Is Tolerable and Improves ORR, CR, PFS and OS
By
Cleveland Clinic's 20th Annual ASH Review
FEATURING
Brian Hill
By
Cleveland Clinic's 20th Annual ASH Review
FEATURING
Brian Hill
0 views
April 14, 2020
Comments 0
Login to view comments.
Click here to Login
Malignant Hematology